Cite
HARVARD Citation
Toussi, S. et al. (2022). Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment. Clinical pharmacology & therapeutics. 112 (4), pp. 892-900. [Online].